Week Ahead 

Preview: Croda's dividend potential

Preview: Croda's dividend potential

Earlier this month, Croda International (CRDA) bought a pharmaceutical company that specialises in the delivery of drugs through lipids for $185m (£146m). The all-cash acquisition, done with a three-year loan, shows the confidence the chemicals company has despite the effect of Covid-19 on the economy. The new addition, Avanti Polar Lipids, will also help Croda sell its ingredients for “early-stage pharmaceutical research”, the company said. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now